
0:00
35:33
Every framework this season assumes the data under the model are trustworthy. Sam and Sarah read what the rulebook actually requires: ALCOA and its pluses from FDA's 2018 Data Integrity Q&A, PIC/S PI 041 and the Annex 11 revision; FDA's 2025 'fit for use', which adds relevance to reliability; and the data-governance clauses of the AI Act, EMA's reflection paper and draft Annex 22. The Annex 11 revision turns the training-data pipeline into a GMP computerised system, with validated transfers, unique accounts, audit trails and backup. Then the gap: nobody says how to get from a historian, a batch record and a LIMS to a fit-for-use dataset. The soft sensor's training set is interrogated attribute by attribute, the batch model's golden batches become exclusion decisions, the camera's labels and vials get their clauses, and the agentic assistant's data turn out to be documents, versions and all.
Researched, scripted and voiced by AI systems under Jack Prior's direction. Sam and Sarah are AI characters; nothing in the episode is Jack speaking, and none of it is a statement of his views or his employer's. Generative AI can be confidently wrong — check the sources. Corrections: [email protected].
Transcript: https://jackprior.ai/podcast/transcript/06-data.html
Documents discussed:
Annex 11 — Computerised Systems (revision): https://health.ec.europa.eu/consultations/stakeholders-consultation-eudralex-volume-4-good-manufacturing-practice-guidelines-chapter-4-annex_en
Data Integrity and Compliance with Drug CGMP Q&A: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/data-integrity-and-compliance-drug-cgmp-questions-and-answers
PI 041-1: https://picscheme.org/docview/4234
Considerations for the Use of AI to Support Regulatory Decision-Making for Drug and Biological Products: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-artificial-intelligence-support-regulatory-decision-making-drug-and-biological
Regulation (EU) 2024/1689 — AI Act: https://eur-lex.europa.eu/eli/reg/2024/1689/oj/eng
Reflection Paper on the Use of AI in the Medicinal Product Lifecycle: https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-use-artificial-intelligence-ai-medicinal-product-lifecycle_en.pdf
Annex 22 — Artificial Intelligence: https://picscheme.org/docview/9715
AI CMC Regulatory Landscape: https://jackprior.ai/ai-cmc-landscape/
Fact check: 69 factual claims in this episode were checked against the source documents by an independent AI pass: 65 are supported by the primary text, 4 are confirmed by official web sources, 0 rest on secondary sources or are hedged as such (listed in the report), 0 open. Full report: https://jackprior.ai/podcast/factcheck/06-data.html
More episodes from "AI in Biopharma Manufacturing: Are We There Yet?"



Don't miss an episode of “AI in Biopharma Manufacturing: Are We There Yet?” and subscribe to it in the GetPodcast app.








